메뉴 건너뛰기




Volumn 32, Issue 25, 2014, Pages 2765-2772

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

(23)  Motzer, Robert J a   Barrios, Carlos H b   Kim, Tae Min c   Falcon, Silvia e   Cosgriff, Thomas f   Harker, W Graydon g   Srimuninnimit, Vichien h   Pittman, Ken i   Sabbatini, Roberto j   Rha, Sun Young d   Flaig, Thomas W k   Page, Ray l   Bavbek, Sevil m   Beck, J Thaddeus n   Patel, Poulam o   Cheung, Foon Yiu p   Yadav, Sunil q   Schiff, Edward M s   Wang, Xufang s   Niolat, Julie t   more..


Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EVEROLIMUS; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN;

EID: 84906815674     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.6911     Document Type: Article
Times cited : (315)

References (10)
  • 2
    • 84866594008 scopus 로고    scopus 로고
    • Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • Escudier B, Eisen T, Porta C, et al: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23: vii65-vii71, 2012 (suppl 7)
    • (2012) Ann Oncol , vol.23 , Issue.SUPPL. 7
    • Escudier, B.1    Eisen, T.2    Porta, C.3
  • 3
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renalcell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 4
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 3584-3590
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 5
    • 77956227464 scopus 로고    scopus 로고
    • Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors
    • Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116:4256-4265, 2010
    • (2010) Cancer , vol.116 , pp. 4256-4265
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 6
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 289-296
    • Motzer, R.J.1    Bacik, J.2    Murphy, B.A.3
  • 7
    • 79956150537 scopus 로고    scopus 로고
    • A proof of concept phase II non-inferiority criterion
    • Neuenschwander B, Rouyrre N, Hollaender N, et al: A proof of concept phase II non-inferiority criterion. Stat Med 30:1618-1627, 2011
    • (2011) Stat Med , vol.30 , pp. 1618-1627
    • Neuenschwander, B.1    Rouyrre, N.2    Hollaender, N.3
  • 8
    • 83055193550 scopus 로고    scopus 로고
    • Calibrated Bayes, for statistics in general, and missing data in particular
    • Little R: Calibrated Bayes, for statistics in general, and missing data in particular. Stat Sci 26:162-174, 2011
    • (2011) Stat Sci , vol.26 , pp. 162-174
    • Little, R.1
  • 9
    • 33747474436 scopus 로고    scopus 로고
    • Calibrated Bayes: A Bayes/frequentist roadmap
    • Little R: Calibrated Bayes: A Bayes/frequentist roadmap. Am Stat 60:1-11, 2006
    • (2006) Am Stat , vol.60 , pp. 1-11
    • Little, R.1
  • 10
    • 33644792767 scopus 로고    scopus 로고
    • Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement
    • Piaggio G, Elbourne DR, Altman DG, et al: Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 295:1152-1160, 2006
    • (2006) JAMA , vol.295 , pp. 1152-1160
    • Piaggio, G.1    Elbourne, D.R.2    Altman, D.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.